Nonrandomized. Subcutaneous IFN beta-1a versus intramuscular IFN beta-1a versus untreated patients
86 RRMS
2 years
IFN beta-1a reduced gray matter atrophy rates, while glatiramer acetate did not. Progression of regional gray matter volume loss differs between patients treated with different immunomodulatory agents.
Randomized. Subcutaneous IFN beta-1a versus intramuscular IFN beta-1a versus glatiramer acetate
141 RRMS
2 years
Effect of subcutaneous IFN beta-1a in preventing new cortical lesions was higher compared to both intramuscular IFN beta-1a and glatiramer acetate. Gray matter fraction decrease did not differ significantly among treatment groups.
Nonrandomized. Natalizumab versus other IMAs (subcutaneous IFN beta-1a, intramuscular IFN beta-1a, or glatiramer acetate)
120 RRMS
2 years
Natalizumab treatment results in greater decreases in the rate of accumulation of cortical lesions and the progression of cortical atrophy as compared to other immunomodulatory agents.